Pub Date : 2024-11-01Epub Date: 2024-10-10DOI: 10.1016/j.ebiom.2024.105394
Isabell Wagenhäuser, Kerstin Knies, Tamara Pscheidl, Michael Eisenmann, Sven Flemming, Nils Petri, Miriam McDonogh, Agmal Scherzad, Daniel Zeller, Anja Gesierich, Anna Katharina Seitz, Regina Taurines, Ralf-Ingo Ernestus, Johannes Forster, Dirk Weismann, Benedikt Weißbrich, Johannes Liese, Christoph Härtel, Oliver Kurzai, Lars Dölken, Alexander Gabel, Manuel Krone
Background: SARS-CoV-2 antigen rapid detection tests (RDTs) emerged as point-of-care diagnostics alongside reverse transcription polymerase chain reaction (RT-qPCR) as reference.
Methods: In a prospective performance assessment from 12 November 2020 to 30 June 2023 at a single centre tertiary care hospital, the sensitivity and specificity (primary endpoints) of RDTs from three manufacturers (NADAL®, Panbio™, MEDsan®) were compared to RT-qPCR as reference standard among patients, accompanying persons and staff aged ≥ six month in large-scale, clinical screening use. Regression models were used to assess influencing factors on RDT performance (secondary endpoints).
Findings: Among 78,798 paired RDT/RT-qPCR results analysed, overall RDT sensitivity was 34.5% (695/2016; 95% CI 32.4-36.6%), specificity 99.6% (76,503/76,782; 95% CI 99.6-99.7%). Over the pandemic course, sensitivity decreased in line with a lower rate of individuals showing typical COVID-19 symptoms. The lasso regression model showed that a higher viral load and typical COVID-19 symptoms were directly significantly correlated with the likelihood of a positive RDT result in SARS-CoV-2 infection, whereas age, sex, vaccination status, and the Omicron VOC were not.
Interpretation: The decline in RDT sensitivity throughout the pandemic can primarily be attributed to the reduced prevalence of symptomatic infections among vaccinated individuals and individuals infected with Omicron VOC. RDTs remain valuable for detecting SARS-CoV-2 in symptomatic individuals and offer potential for detecting other respiratory pathogens in the post-pandemic era, underscoring their importance in infection control efforts.
Funding: German Federal Ministry of Education and Research (BMBF), Free State of Bavaria, Bavarian State Ministry of Health and Care.
{"title":"SARS-CoV-2 antigen rapid detection tests: test performance during the COVID-19 pandemic and the impact of COVID-19 vaccination.","authors":"Isabell Wagenhäuser, Kerstin Knies, Tamara Pscheidl, Michael Eisenmann, Sven Flemming, Nils Petri, Miriam McDonogh, Agmal Scherzad, Daniel Zeller, Anja Gesierich, Anna Katharina Seitz, Regina Taurines, Ralf-Ingo Ernestus, Johannes Forster, Dirk Weismann, Benedikt Weißbrich, Johannes Liese, Christoph Härtel, Oliver Kurzai, Lars Dölken, Alexander Gabel, Manuel Krone","doi":"10.1016/j.ebiom.2024.105394","DOIUrl":"10.1016/j.ebiom.2024.105394","url":null,"abstract":"<p><strong>Background: </strong>SARS-CoV-2 antigen rapid detection tests (RDTs) emerged as point-of-care diagnostics alongside reverse transcription polymerase chain reaction (RT-qPCR) as reference.</p><p><strong>Methods: </strong>In a prospective performance assessment from 12 November 2020 to 30 June 2023 at a single centre tertiary care hospital, the sensitivity and specificity (primary endpoints) of RDTs from three manufacturers (NADAL®, Panbio™, MEDsan®) were compared to RT-qPCR as reference standard among patients, accompanying persons and staff aged ≥ six month in large-scale, clinical screening use. Regression models were used to assess influencing factors on RDT performance (secondary endpoints).</p><p><strong>Findings: </strong>Among 78,798 paired RDT/RT-qPCR results analysed, overall RDT sensitivity was 34.5% (695/2016; 95% CI 32.4-36.6%), specificity 99.6% (76,503/76,782; 95% CI 99.6-99.7%). Over the pandemic course, sensitivity decreased in line with a lower rate of individuals showing typical COVID-19 symptoms. The lasso regression model showed that a higher viral load and typical COVID-19 symptoms were directly significantly correlated with the likelihood of a positive RDT result in SARS-CoV-2 infection, whereas age, sex, vaccination status, and the Omicron VOC were not.</p><p><strong>Interpretation: </strong>The decline in RDT sensitivity throughout the pandemic can primarily be attributed to the reduced prevalence of symptomatic infections among vaccinated individuals and individuals infected with Omicron VOC. RDTs remain valuable for detecting SARS-CoV-2 in symptomatic individuals and offer potential for detecting other respiratory pathogens in the post-pandemic era, underscoring their importance in infection control efforts.</p><p><strong>Funding: </strong>German Federal Ministry of Education and Research (BMBF), Free State of Bavaria, Bavarian State Ministry of Health and Care.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"109 ","pages":"105394"},"PeriodicalIF":9.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-10-18DOI: 10.1016/j.ebiom.2024.105392
Tianxiang Kong, Pei Du, Renyi Ma, Han Wang, Xuehui Ma, Jian Lu, Zhengrong Gao, Hai Qi, Ruiqi Li, Hao Zhang, Fei Xia, Yuanlang Liu, Ruyu Wang, Kai Duan, Zejun Wang, Qihui Wang, George F Gao
Background: Mpox has spread to many countries around the world. While the existing live attenuated mpox vaccines are effective, advances in 21st century technologies now enable the development of vaccines with more specific antigens, clearer mechanisms, and more controllable side effects.
Methods: We systematically evaluated the immunogenicity and protective efficacy of the A35R, M1R and B6R antigens of the mpox virus (MPXV). With these findings, we designed three single-chain trivalent mRNA vaccines (AMAB-wt, AMAB-C140S and AMB-C140S) by integrating the soluble regions of these antigens into single mRNA-encoded polypeptides based on their protein structures. Then, the immunogenicity and protective efficacy of these single-chain mRNA vaccines were evaluated in mice models against both VACV and MPXV.
Findings: The three single-chain vaccines elicited neutralising antibodies that effectively neutralised both VACV and MPXV. The single-chain vaccines or cocktail vaccine containing mRNAs encoding soluble antigen (sA35R + sM1R + sB6R) exhibited 100% or 80% protection against a lethal dose of VACV challenge, while the cocktail of full-length antigens (A35 + M1 + B6) and the live attenuated vaccine, VACV Tian Tan (VACV-VTT), completely failed to protect mice. Moreover, the single-chain vaccines significantly reduced viral load in the lungs and ovaries of MPXV-challenged mice.
Interpretation: Compared with the cocktail vaccines, our single-chain designs demonstrated similar or superior immunogenicity and protective efficacy. Importantly, the simplicity of the single-chain vaccines enhances both the controllability and accessibility of mpox vaccines. We believe these single-chain vaccines qualify as the next-generation mpox vaccines.
Funding: National Natural Science Foundation of China and Youth Innovation Promotion Association of the CAS.
{"title":"Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virus.","authors":"Tianxiang Kong, Pei Du, Renyi Ma, Han Wang, Xuehui Ma, Jian Lu, Zhengrong Gao, Hai Qi, Ruiqi Li, Hao Zhang, Fei Xia, Yuanlang Liu, Ruyu Wang, Kai Duan, Zejun Wang, Qihui Wang, George F Gao","doi":"10.1016/j.ebiom.2024.105392","DOIUrl":"10.1016/j.ebiom.2024.105392","url":null,"abstract":"<p><strong>Background: </strong>Mpox has spread to many countries around the world. While the existing live attenuated mpox vaccines are effective, advances in 21st century technologies now enable the development of vaccines with more specific antigens, clearer mechanisms, and more controllable side effects.</p><p><strong>Methods: </strong>We systematically evaluated the immunogenicity and protective efficacy of the A35R, M1R and B6R antigens of the mpox virus (MPXV). With these findings, we designed three single-chain trivalent mRNA vaccines (AMAB-wt, AMAB-C140S and AMB-C140S) by integrating the soluble regions of these antigens into single mRNA-encoded polypeptides based on their protein structures. Then, the immunogenicity and protective efficacy of these single-chain mRNA vaccines were evaluated in mice models against both VACV and MPXV.</p><p><strong>Findings: </strong>The three single-chain vaccines elicited neutralising antibodies that effectively neutralised both VACV and MPXV. The single-chain vaccines or cocktail vaccine containing mRNAs encoding soluble antigen (sA35R + sM1R + sB6R) exhibited 100% or 80% protection against a lethal dose of VACV challenge, while the cocktail of full-length antigens (A35 + M1 + B6) and the live attenuated vaccine, VACV Tian Tan (VACV-VTT), completely failed to protect mice. Moreover, the single-chain vaccines significantly reduced viral load in the lungs and ovaries of MPXV-challenged mice.</p><p><strong>Interpretation: </strong>Compared with the cocktail vaccines, our single-chain designs demonstrated similar or superior immunogenicity and protective efficacy. Importantly, the simplicity of the single-chain vaccines enhances both the controllability and accessibility of mpox vaccines. We believe these single-chain vaccines qualify as the next-generation mpox vaccines.</p><p><strong>Funding: </strong>National Natural Science Foundation of China and Youth Innovation Promotion Association of the CAS.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"109 ","pages":"105392"},"PeriodicalIF":9.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-11-05DOI: 10.1016/j.ebiom.2024.105449
Nour Amwas, Chu-Hsuan Chiu, Diana Gumber, Leo D Wang
{"title":"Adoptive T cell therapies for solid tumors: T(I)ME is of the essence.","authors":"Nour Amwas, Chu-Hsuan Chiu, Diana Gumber, Leo D Wang","doi":"10.1016/j.ebiom.2024.105449","DOIUrl":"10.1016/j.ebiom.2024.105449","url":null,"abstract":"","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"109 ","pages":"105449"},"PeriodicalIF":9.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-30DOI: 10.1016/j.ebiom.2024.105412
Yongtao Wang, Emeli Chatterjee, Guoping Li, Jiahong Xu, Junjie Xiao
Force-sensing biophysical cues in microenvironment, including extracellular matrix performances, stretch-mediated mechanics, shear stress and flow-induced hemodynamics, have a significant influence in regulating vascular morphogenesis and cardiac remodeling by mechanotransduction. Once cells perceive these extracellular mechanical stimuli, Piezo activation promotes calcium influx by forming integrin-adhesion-coupling receptors. This induces robust contractility of cytoskeleton structures to further transmit biomechanical alternations into nuclei by regulating Hippo-Yes associated protein (YAP) signaling pathway between cytoplasmic and nuclear translocation. Although biomechanical stimuli are widely studied in cardiovascular diseases, the expression of force-sensing proteins in response to cardiovascular mechanotransduction has not been systematically concluded. Therefore, this review will summarize the force-sensing Piezo, cytoskeleton and YAP proteins to mediate extracellular mechanics, and also give the prominent emphasis on intrinsic connection of these mechanical proteins and cardiovascular mechanotransduction. Extensive insights into cardiovascular mechanics may provide some new strategies for cardiovascular clinical therapy.
{"title":"Force-sensing protein expression in response to cardiovascular mechanotransduction.","authors":"Yongtao Wang, Emeli Chatterjee, Guoping Li, Jiahong Xu, Junjie Xiao","doi":"10.1016/j.ebiom.2024.105412","DOIUrl":"10.1016/j.ebiom.2024.105412","url":null,"abstract":"<p><p>Force-sensing biophysical cues in microenvironment, including extracellular matrix performances, stretch-mediated mechanics, shear stress and flow-induced hemodynamics, have a significant influence in regulating vascular morphogenesis and cardiac remodeling by mechanotransduction. Once cells perceive these extracellular mechanical stimuli, Piezo activation promotes calcium influx by forming integrin-adhesion-coupling receptors. This induces robust contractility of cytoskeleton structures to further transmit biomechanical alternations into nuclei by regulating Hippo-Yes associated protein (YAP) signaling pathway between cytoplasmic and nuclear translocation. Although biomechanical stimuli are widely studied in cardiovascular diseases, the expression of force-sensing proteins in response to cardiovascular mechanotransduction has not been systematically concluded. Therefore, this review will summarize the force-sensing Piezo, cytoskeleton and YAP proteins to mediate extracellular mechanics, and also give the prominent emphasis on intrinsic connection of these mechanical proteins and cardiovascular mechanotransduction. Extensive insights into cardiovascular mechanics may provide some new strategies for cardiovascular clinical therapy.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"110 ","pages":"105412"},"PeriodicalIF":9.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-24DOI: 10.1016/j.ebiom.2024.105411
Andy Y An, Erica Acton, Olubukola T Idoko, Casey P Shannon, Travis M Blimkie, Reza Falsafi, Oghenebrume Wariri, Abdulazeez Imam, Tida Dibbasey, Tue Bjerg Bennike, Kinga K Smolen, Joann Diray-Arce, Rym Ben-Othman, Sebastiano Montante, Asimenia Angelidou, Oludare A Odumade, David Martino, Scott J Tebbutt, Ofer Levy, Hanno Steen, Tobias R Kollmann, Beate Kampmann, Robert E W Hancock, Amy H Lee
Background: Neonatal sepsis is a deadly disease with non-specific clinical signs, delaying diagnosis and treatment. There remains a need for early biomarkers to facilitate timely intervention. Our objective was to identify neonatal sepsis gene expression biomarkers that could predict sepsis at birth, prior to clinical presentation.
Methods: Among 720 initially healthy full-term neonates in two hospitals (The Gambia, West Africa), we identified 21 newborns who were later hospitalized for sepsis in the first 28 days of life, split into early-onset sepsis (EOS, onset ≤7 days of life) and late-onset sepsis (LOS, onset 8-28 days of life), 12 neonates later hospitalized for localized infection without evidence of systemic involvement, and 33 matched control neonates who remained healthy. RNA-seq was performed on peripheral blood collected at birth when all neonates were healthy and also within the first week of life to identify differentially expressed genes (DEGs). Machine learning methods (sPLS-DA, LASSO) identified genes expressed at birth that predicted onset of neonatal sepsis at a later time.
Findings: Neonates who later developed EOS already had ∼1000 DEGs at birth when compared to control neonates or those who later developed a localized infection or LOS. Based on these DEGs, a 4-gene signature (HSPH1, BORA, NCAPG2, PRIM1) for predicting EOS at birth was developed (training AUC = 0.94, sensitivity = 0.93, specificity = 0.92) and validated in an external cohort (validation AUC = 0.72, sensitivity = 0.83, and specificity = 0.83). Additionally, during the first week of life, EOS disrupted expression of >1800 genes including those influencing immune and metabolic transitions observed in healthy controls.
Interpretation: Despite appearing healthy at birth, neonates who later developed EOS already had distinct whole blood gene expression changes at birth, which enabled the development of a 4-gene predictive signature for EOS. This could facilitate early recognition and treatment of neonatal sepsis, potentially mitigating its long-term sequelae.
{"title":"Predictive gene expression signature diagnoses neonatal sepsis before clinical presentation.","authors":"Andy Y An, Erica Acton, Olubukola T Idoko, Casey P Shannon, Travis M Blimkie, Reza Falsafi, Oghenebrume Wariri, Abdulazeez Imam, Tida Dibbasey, Tue Bjerg Bennike, Kinga K Smolen, Joann Diray-Arce, Rym Ben-Othman, Sebastiano Montante, Asimenia Angelidou, Oludare A Odumade, David Martino, Scott J Tebbutt, Ofer Levy, Hanno Steen, Tobias R Kollmann, Beate Kampmann, Robert E W Hancock, Amy H Lee","doi":"10.1016/j.ebiom.2024.105411","DOIUrl":"https://doi.org/10.1016/j.ebiom.2024.105411","url":null,"abstract":"<p><strong>Background: </strong>Neonatal sepsis is a deadly disease with non-specific clinical signs, delaying diagnosis and treatment. There remains a need for early biomarkers to facilitate timely intervention. Our objective was to identify neonatal sepsis gene expression biomarkers that could predict sepsis at birth, prior to clinical presentation.</p><p><strong>Methods: </strong>Among 720 initially healthy full-term neonates in two hospitals (The Gambia, West Africa), we identified 21 newborns who were later hospitalized for sepsis in the first 28 days of life, split into early-onset sepsis (EOS, onset ≤7 days of life) and late-onset sepsis (LOS, onset 8-28 days of life), 12 neonates later hospitalized for localized infection without evidence of systemic involvement, and 33 matched control neonates who remained healthy. RNA-seq was performed on peripheral blood collected at birth when all neonates were healthy and also within the first week of life to identify differentially expressed genes (DEGs). Machine learning methods (sPLS-DA, LASSO) identified genes expressed at birth that predicted onset of neonatal sepsis at a later time.</p><p><strong>Findings: </strong>Neonates who later developed EOS already had ∼1000 DEGs at birth when compared to control neonates or those who later developed a localized infection or LOS. Based on these DEGs, a 4-gene signature (HSPH1, BORA, NCAPG2, PRIM1) for predicting EOS at birth was developed (training AUC = 0.94, sensitivity = 0.93, specificity = 0.92) and validated in an external cohort (validation AUC = 0.72, sensitivity = 0.83, and specificity = 0.83). Additionally, during the first week of life, EOS disrupted expression of >1800 genes including those influencing immune and metabolic transitions observed in healthy controls.</p><p><strong>Interpretation: </strong>Despite appearing healthy at birth, neonates who later developed EOS already had distinct whole blood gene expression changes at birth, which enabled the development of a 4-gene predictive signature for EOS. This could facilitate early recognition and treatment of neonatal sepsis, potentially mitigating its long-term sequelae.</p><p><strong>Funding: </strong>CIHR and NIH/NIAID.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":" ","pages":"105411"},"PeriodicalIF":9.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-09-14DOI: 10.1016/j.ebiom.2024.105341
Sabrina E Wang, Vivian Viallon, Matthew Lee, Niki Dimou, Fergus Hamilton, Carine Biessy, Tracy O'Mara, Maria Kyrgiou, Emma J Crosbie, Therese Truong, Gianluca Severi, Rudolf Kaaks, Renée Turzanski Fortner, Matthias B Schulze, Benedetta Bendinelli, Sieri Sabina, Rosario Tumino, Carlotta Sacerdote, Salvatore Panico, Marta Crous-Bou, Maria-Jose Sánchez, Amaia Aizpurua, Daniel Rodriguez Palacios, Marcela Guevara, Ruth C Travis, Konstantinos K Tsilidis, Alicia Heath, James Yarmolinsky, Sabina Rinaldi, Marc J Gunter, Laure Dossus
Background: Inflammation and immune dysregulation are hypothesized contributors to endometrial carcinogenesis; however, the precise underlying mechanisms remain unclear.
Methods: We measured pre-diagnostically 152 plasma protein biomarkers in 624 endometrial cancer case-control pairs nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Odds ratios (ORs) were estimated using conditional logistic regression, accounting for confounding and multiple comparisons. Proteins considered as associated with endometrial cancer risk were further tested in a two-sample Mendelian randomization (MR) analysis using summary data from the UK Biobank (n = 52,363) and the Endometrial Cancer Association Consortium (12,270 cases and 46,126 controls).
Findings: In the EPIC nested case-control study, IL-6 [OR per NPX (doubling of concentration) = 1.28 (95% confidence interval (CI) 1.03-1.57)], HGF [1.48 (1.06-2.07)], PIK3AP1 [1.22 (1.00-1.50)] and CLEC4G [1.52 (1.00-2.32)] were positively associated; HSD11B1 [0.67 (0.49-0.91)], SCF [0.68 (0.49-0.94)], and CCL25 [0.80 (0.65-0.99)] were inversely associated with endometrial cancer risk; all estimates had multiple comparisons adjusted P-value > 0.05. In complementary MR analysis, IL-6 [OR per inverse-rank normalized NPX = 1.19 (95% CI 1.04-1.36)] and HSD11B1 [0.91 (0.84-0.99)] were associated with endometrial cancer risk.
Interpretation: Altered IL-6 signalling and reduced glucocorticoid activity via HSD11B1 might play important roles in endometrial carcinogenesis.
Funding: Funding for IIG_FULL_2021_008 was obtained from Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant programme; Funding for INCA_15849 was obtained from Institut National du Cancer (INCa).
{"title":"Circulating inflammatory and immune response proteins and endometrial cancer risk: a nested case-control study and Mendelian randomization analyses.","authors":"Sabrina E Wang, Vivian Viallon, Matthew Lee, Niki Dimou, Fergus Hamilton, Carine Biessy, Tracy O'Mara, Maria Kyrgiou, Emma J Crosbie, Therese Truong, Gianluca Severi, Rudolf Kaaks, Renée Turzanski Fortner, Matthias B Schulze, Benedetta Bendinelli, Sieri Sabina, Rosario Tumino, Carlotta Sacerdote, Salvatore Panico, Marta Crous-Bou, Maria-Jose Sánchez, Amaia Aizpurua, Daniel Rodriguez Palacios, Marcela Guevara, Ruth C Travis, Konstantinos K Tsilidis, Alicia Heath, James Yarmolinsky, Sabina Rinaldi, Marc J Gunter, Laure Dossus","doi":"10.1016/j.ebiom.2024.105341","DOIUrl":"10.1016/j.ebiom.2024.105341","url":null,"abstract":"<p><strong>Background: </strong>Inflammation and immune dysregulation are hypothesized contributors to endometrial carcinogenesis; however, the precise underlying mechanisms remain unclear.</p><p><strong>Methods: </strong>We measured pre-diagnostically 152 plasma protein biomarkers in 624 endometrial cancer case-control pairs nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Odds ratios (ORs) were estimated using conditional logistic regression, accounting for confounding and multiple comparisons. Proteins considered as associated with endometrial cancer risk were further tested in a two-sample Mendelian randomization (MR) analysis using summary data from the UK Biobank (n = 52,363) and the Endometrial Cancer Association Consortium (12,270 cases and 46,126 controls).</p><p><strong>Findings: </strong>In the EPIC nested case-control study, IL-6 [OR per NPX (doubling of concentration) = 1.28 (95% confidence interval (CI) 1.03-1.57)], HGF [1.48 (1.06-2.07)], PIK3AP1 [1.22 (1.00-1.50)] and CLEC4G [1.52 (1.00-2.32)] were positively associated; HSD11B1 [0.67 (0.49-0.91)], SCF [0.68 (0.49-0.94)], and CCL25 [0.80 (0.65-0.99)] were inversely associated with endometrial cancer risk; all estimates had multiple comparisons adjusted P-value > 0.05. In complementary MR analysis, IL-6 [OR per inverse-rank normalized NPX = 1.19 (95% CI 1.04-1.36)] and HSD11B1 [0.91 (0.84-0.99)] were associated with endometrial cancer risk.</p><p><strong>Interpretation: </strong>Altered IL-6 signalling and reduced glucocorticoid activity via HSD11B1 might play important roles in endometrial carcinogenesis.</p><p><strong>Funding: </strong>Funding for IIG_FULL_2021_008 was obtained from Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant programme; Funding for INCA_15849 was obtained from Institut National du Cancer (INCa).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"108 ","pages":"105341"},"PeriodicalIF":9.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-09-19DOI: 10.1016/j.ebiom.2024.105356
Trinh T T Tran, Cao Dai Phung, Brendon Z J Yeo, Rebecca C Prajogo, Migara K Jayasinghe, Ju Yuan, Daniel S W Tan, Eric Y M Yeo, Boon Cher Goh, Wai Leong Tam, Minh T N Le
Background: Tyrosine kinase inhibitors (TKIs) are currently the standard therapy for patients with non-small cell lung cancer (NSCLC) bearing mutations in epidermal growth factor receptor (EGFR). Unfortunately, drug-acquired resistance is inevitable due to the emergence of new mutations in EGFR. Moreover, the TKI treatment is associated with severe toxicities due to the unspecific inhibition of wild-type (WT) EGFR. Thus, treatment that is customised to an individual's genetic alterations in EGFR may offer greater therapeutic benefits for patients with NSCLC.
Methods: In this study, we demonstrate a new therapeutic strategy utilising customised antisense oligonucleotides (ASOs) to selectively target activating mutations in the EGFR gene in an individualised manner that can overcome drug-resistant mutations. We use extracellular vesicles (EVs) as a vehicle to deliver ASOs to NSCLC cells.
Findings: Specifically guided by the mutational profile identified in NSCLC patients, we have successfully developed ASOs that selectively inhibit point mutations in the EGFR gene, including L858R and T790M, while sparing the WT EGFR. Delivery of the EGFR-targeting ASOs by EVs significantly reduced tumour growth in xenograft models of EGFR-L858R/T790M-driven NSCLC. Importantly, we have also shown that EGFR-targeting ASOs exhibit more potent anti-cancer effect than TKIs in NSCLC with EGFR mutations, effectively suppressing a patient-derived TKI-resistant NSCLC tumour.
Interpretation: Overall, by harnessing the specificity and efficacy of ASOs, we present an effective and adaptable therapeutic platform for NSCLC treatment.
Funding: This study was funded by Singapore's Ministry of Health (NMRC/OFIRG/MOH-000643-00, OFIRG21nov-0068, NMRC/OFLCG/002-2018, OFYIRG22jul-0034), National Research Foundation (NRF-NRFI08-2022, NRF-CRP22-2019-0003, NRF-CRP23-2019-0004), A∗STAR, and Ministry of Education.
{"title":"Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer.","authors":"Trinh T T Tran, Cao Dai Phung, Brendon Z J Yeo, Rebecca C Prajogo, Migara K Jayasinghe, Ju Yuan, Daniel S W Tan, Eric Y M Yeo, Boon Cher Goh, Wai Leong Tam, Minh T N Le","doi":"10.1016/j.ebiom.2024.105356","DOIUrl":"10.1016/j.ebiom.2024.105356","url":null,"abstract":"<p><strong>Background: </strong>Tyrosine kinase inhibitors (TKIs) are currently the standard therapy for patients with non-small cell lung cancer (NSCLC) bearing mutations in epidermal growth factor receptor (EGFR). Unfortunately, drug-acquired resistance is inevitable due to the emergence of new mutations in EGFR. Moreover, the TKI treatment is associated with severe toxicities due to the unspecific inhibition of wild-type (WT) EGFR. Thus, treatment that is customised to an individual's genetic alterations in EGFR may offer greater therapeutic benefits for patients with NSCLC.</p><p><strong>Methods: </strong>In this study, we demonstrate a new therapeutic strategy utilising customised antisense oligonucleotides (ASOs) to selectively target activating mutations in the EGFR gene in an individualised manner that can overcome drug-resistant mutations. We use extracellular vesicles (EVs) as a vehicle to deliver ASOs to NSCLC cells.</p><p><strong>Findings: </strong>Specifically guided by the mutational profile identified in NSCLC patients, we have successfully developed ASOs that selectively inhibit point mutations in the EGFR gene, including L858R and T790M, while sparing the WT EGFR. Delivery of the EGFR-targeting ASOs by EVs significantly reduced tumour growth in xenograft models of EGFR-L858R/T790M-driven NSCLC. Importantly, we have also shown that EGFR-targeting ASOs exhibit more potent anti-cancer effect than TKIs in NSCLC with EGFR mutations, effectively suppressing a patient-derived TKI-resistant NSCLC tumour.</p><p><strong>Interpretation: </strong>Overall, by harnessing the specificity and efficacy of ASOs, we present an effective and adaptable therapeutic platform for NSCLC treatment.</p><p><strong>Funding: </strong>This study was funded by Singapore's Ministry of Health (NMRC/OFIRG/MOH-000643-00, OFIRG21nov-0068, NMRC/OFLCG/002-2018, OFYIRG22jul-0034), National Research Foundation (NRF-NRFI08-2022, NRF-CRP22-2019-0003, NRF-CRP23-2019-0004), A∗STAR, and Ministry of Education.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"108 ","pages":"105356"},"PeriodicalIF":9.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-09-19DOI: 10.1016/j.ebiom.2024.105340
Han Wang, Qi Xu, Heng Heng, Wenxing Zhao, Hongyuhang Ni, Kaichao Chen, Bill Kwan Wai Chan, Yang Tang, Miaomiao Xie, Mingxiu Peng, Edward Wai Chi Chan, Guan Yang, Sheng Chen
Background: The continuous emergence of multidrug-resistant (MDR) Acinetobacter baumannii (Ab) strains poses further challenges in its control and clinical management. It is necessary to decipher the mechanisms underlying the high mortality of Ab infections to explore unconventional strategies for controlling outbreaks of drug-resistant infections.
Methods: The immune responses of Ab sepsis infection were investigated using flow cytometry, RNA-seq, qRT-PCR, and ELISA and scRNA-seq. The detailed pathways mediating Ab immune responses were also depicted and a specific therapy was developed based on the understanding of the mechanisms underlying Ab-induced cytokine storms.
Findings: The results highlighted the critical role of alveolar and interstitial macrophages as targets of Ab during the infection process. These cells were found to undergo polarization towards the M1 phenotype, triggering a cytokine storm that eventually caused the death of the host. The polarization and excessive inflammatory response mediated by macrophages were mainly regulated by the TLR2/Myd88/NF-κB signaling pathway. Suppression of Ab-triggered inflammatory responses and M1 polarization by the drug naproxen (NPXS) was shown to confer full protection of mice from lethal infections.
Interpretation: The findings in this work depict the major mechanisms underlying the high mortality rate of Ab infections and highlight the clinical potential application of anti-inflammatory drugs or immunosuppressants in reducing the mortality of such infections, including those caused by MDR strains.
Funding: Funding sources are described in the acknowledgments section.
背景:耐多药(MDR)鲍曼不动杆菌(Ab)菌株的不断出现为其控制和临床管理带来了更多挑战。有必要破译鲍曼不动杆菌感染高死亡率的内在机制,以探索控制耐药感染爆发的非常规策略:方法:使用流式细胞术、RNA-seq、qRT-PCR、ELISA 和 scRNA-seq 研究了 Ab 败血症感染的免疫反应。研究还描绘了介导 Ab 免疫反应的详细途径,并根据对 Ab 诱导细胞因子风暴机制的了解开发了一种特殊疗法:研究结果:研究结果强调了肺泡和间质巨噬细胞在感染过程中作为Ab靶点的关键作用。研究发现,这些细胞向 M1 表型极化,引发细胞因子风暴,最终导致宿主死亡。巨噬细胞的极化和过度炎症反应主要由 TLR2/Myd88/NF-κB 信号通路调控。研究表明,萘普生(NPXS)能抑制 Ab 触发的炎症反应和 M1 极化,从而完全保护小鼠免受致命感染:这项工作的发现描述了Ab感染高死亡率的主要机制,并强调了抗炎药物或免疫抑制剂在降低此类感染(包括由MDR菌株引起的感染)死亡率方面的临床应用潜力:资金来源见致谢部分。
{"title":"High mortality of Acinetobacter baumannii infection is attributed to macrophage-mediated induction of cytokine storm but preventable by naproxen.","authors":"Han Wang, Qi Xu, Heng Heng, Wenxing Zhao, Hongyuhang Ni, Kaichao Chen, Bill Kwan Wai Chan, Yang Tang, Miaomiao Xie, Mingxiu Peng, Edward Wai Chi Chan, Guan Yang, Sheng Chen","doi":"10.1016/j.ebiom.2024.105340","DOIUrl":"10.1016/j.ebiom.2024.105340","url":null,"abstract":"<p><strong>Background: </strong>The continuous emergence of multidrug-resistant (MDR) Acinetobacter baumannii (Ab) strains poses further challenges in its control and clinical management. It is necessary to decipher the mechanisms underlying the high mortality of Ab infections to explore unconventional strategies for controlling outbreaks of drug-resistant infections.</p><p><strong>Methods: </strong>The immune responses of Ab sepsis infection were investigated using flow cytometry, RNA-seq, qRT-PCR, and ELISA and scRNA-seq. The detailed pathways mediating Ab immune responses were also depicted and a specific therapy was developed based on the understanding of the mechanisms underlying Ab-induced cytokine storms.</p><p><strong>Findings: </strong>The results highlighted the critical role of alveolar and interstitial macrophages as targets of Ab during the infection process. These cells were found to undergo polarization towards the M1 phenotype, triggering a cytokine storm that eventually caused the death of the host. The polarization and excessive inflammatory response mediated by macrophages were mainly regulated by the TLR2/Myd88/NF-κB signaling pathway. Suppression of Ab-triggered inflammatory responses and M1 polarization by the drug naproxen (NPXS) was shown to confer full protection of mice from lethal infections.</p><p><strong>Interpretation: </strong>The findings in this work depict the major mechanisms underlying the high mortality rate of Ab infections and highlight the clinical potential application of anti-inflammatory drugs or immunosuppressants in reducing the mortality of such infections, including those caused by MDR strains.</p><p><strong>Funding: </strong>Funding sources are described in the acknowledgments section.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"108 ","pages":"105340"},"PeriodicalIF":9.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: To assess the long-term impact of residential air pollution and green space exposure on cause-specific mortality in individuals with type 2 diabetes mellitus (T2DM).
Methods: This study includes 174,063 participants newly diagnosed with T2DM from a prospective cohort in Shanghai, China, enrolled between 2011 and 2013. Residential annual levels of air pollutants, including fine (PM2.5) and coarse (PM2.5-10) particulate matter, nitrogen dioxide (NO2), along with the normalized difference vegetation index (NDVI), were derived from satellite-based exposure models.
Findings: During a median follow-up of 7.9 years (equivalent to 1,333,343 person-years), this study recorded 22,205 deaths. Higher exposure to PM2.5 was significantly associated with increased risks for all mortality outcomes, whilst PM2.5-10 showed no significant impacts. The strongest associations of PM2.5 were observed for diabetes with peripheral vascular diseases [hazard ratio (HR): 2.70; per 10 μg/m3 increase] and gastrointestinal cancer (2.44). Effects of NO2 became significant at concentrations exceeding approximately 45 μg/m³, with the highest associations for lung cancer (1.20) and gastrointestinal cancer (1.19). Conversely, each interquartile range increase in NDVI (0.10) was linked to reduced mortality risks across different causes, with HRs ranging from 0.76 to 1.00. The association between greenness and mortality was partly and significantly mediated by reduced PM2.5 (23.80%) and NO2 (26.60%). There was a significant and negative interaction between NO2 and greenness, but no interaction was found between PM2.5 and greenness.
Interpretation: Our findings highlight the vulnerability of individuals with T2DM to the adverse health effects of air pollution and emphasise the potential protective effects of greenness infrastructure.
Funding: The 6th Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System (GWVI-11.1-22), the National Key Research and Development Program (2022YFC3702701), and the National Natural Science Foundation of China (82030103, 82373532).
{"title":"Association of residential air pollution and green space with all-cause and cause-specific mortality in individuals with diabetes: an 11-year prospective cohort study.","authors":"Chunfeng Wu, Jiangdong Liu, Yanyun Li, Luxin Qin, Ruilong Gu, Jiachen Feng, Lulu Xu, Xia Meng, Jiaxin Chen, Renjie Chen, Yan Shi, Haidong Kan","doi":"10.1016/j.ebiom.2024.105376","DOIUrl":"10.1016/j.ebiom.2024.105376","url":null,"abstract":"<p><strong>Background: </strong>To assess the long-term impact of residential air pollution and green space exposure on cause-specific mortality in individuals with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>This study includes 174,063 participants newly diagnosed with T2DM from a prospective cohort in Shanghai, China, enrolled between 2011 and 2013. Residential annual levels of air pollutants, including fine (PM<sub>2.5</sub>) and coarse (PM<sub>2.5-10</sub>) particulate matter, nitrogen dioxide (NO<sub>2</sub>), along with the normalized difference vegetation index (NDVI), were derived from satellite-based exposure models.</p><p><strong>Findings: </strong>During a median follow-up of 7.9 years (equivalent to 1,333,343 person-years), this study recorded 22,205 deaths. Higher exposure to PM<sub>2.5</sub> was significantly associated with increased risks for all mortality outcomes, whilst PM<sub>2.5-10</sub> showed no significant impacts. The strongest associations of PM<sub>2.5</sub> were observed for diabetes with peripheral vascular diseases [hazard ratio (HR): 2.70; per 10 μg/m<sup>3</sup> increase] and gastrointestinal cancer (2.44). Effects of NO<sub>2</sub> became significant at concentrations exceeding approximately 45 μg/m³, with the highest associations for lung cancer (1.20) and gastrointestinal cancer (1.19). Conversely, each interquartile range increase in NDVI (0.10) was linked to reduced mortality risks across different causes, with HRs ranging from 0.76 to 1.00. The association between greenness and mortality was partly and significantly mediated by reduced PM<sub>2.5</sub> (23.80%) and NO<sub>2</sub> (26.60%). There was a significant and negative interaction between NO<sub>2</sub> and greenness, but no interaction was found between PM<sub>2.5</sub> and greenness.</p><p><strong>Interpretation: </strong>Our findings highlight the vulnerability of individuals with T2DM to the adverse health effects of air pollution and emphasise the potential protective effects of greenness infrastructure.</p><p><strong>Funding: </strong>The 6th Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System (GWVI-11.1-22), the National Key Research and Development Program (2022YFC3702701), and the National Natural Science Foundation of China (82030103, 82373532).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"108 ","pages":"105376"},"PeriodicalIF":9.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-09-30DOI: 10.1016/j.ebiom.2024.105347
Laura Seldeslachts, Frederik Staels, Marina Gkountzinopoulou, Cato Jacobs, Birger Tielemans, Eliane Vanhoffelen, Agustin Reséndiz-Sharpe, Lander De Herdt, Jeason Haughton, Teresa Prezzemolo, Oliver Burton, Simon Feys, Frank L van de Veerdonk, Agostinho Carvalho, Lieve Naesens, Patrick Matthys, Katrien Lagrou, Erik Verbeken, Georgios Chamilos, Joost Wauters, Stephanie Humblet-Baron, Greetje Vande Velde
<p><strong>Background: </strong>Influenza-associated pulmonary aspergillosis (IAPA) is a severe fungal superinfection in critically ill influenza patients that is of incompletely understood pathogenesis. Despite the use of contemporary therapies with antifungal and antivirals, mortality rates remain unacceptably high. We aimed to unravel the IAPA immunopathogenesis as a means to develop adjunctive immunomodulatory therapies.</p><p><strong>Methods: </strong>We used a murine model of IAPA to investigate how influenza predisposes to the development of invasive pulmonary aspergillosis. Immunocompetent mice were challenged with an intranasal instillation of influenza on day 0 followed by an orotracheal inoculation with Aspergillus 4 days later. Mice were monitored daily for overall health status, lung pathology with micro-computed tomography (μCT) and fungal burden with bioluminescence imaging (BLI). At endpoint, high parameter immunophenotyping, spatial transcriptomics, histopathology, dynamic phagosome biogenesis assays with live imaging, immunofluorescence staining, specialized functional phagocytosis and killing assays were performed.</p><p><strong>Findings: </strong>We uncovered an early exuberant influenza-induced interferon-gamma (IFN-γ) production as the major driver of immunopathology in IAPA and delineated the molecular mechanisms. Specifically, excessive IFN-γ production resulted in a defective Th17-immune response, depletion of macrophages, and impaired killing of Aspergillus conidia by macrophages due to the inhibition of NADPH oxidase-dependent activation of LC3-associated phagocytosis (LAP). Markedly, mice with partial or complete genetic ablation of IFN-γ had a restored Th17-immune response, LAP-dependent mechanism of killing and were fully protected from invasive fungal infection.</p><p><strong>Interpretation: </strong>Together, these results identify exuberant viral induced IFN-γ production as a major driver of immune dysfunction in IAPA, paving the way to explore the use of excessive viral-induced IFN-γ as a biomarker and new immunotherapeutic target in IAPA.</p><p><strong>Funding: </strong>This research was funded by the Research Foundation Flanders (FWO), project funding under Grant G053121N to JW, SHB and GVV; G057721N, G0G4820N to GVV; 1506114 N to KL and GVV; KU Leuven internal funds (C24/17/061) to GVV, clinical research funding to JW, Research Foundation Flanders (FWO) aspirant mandate under Grant 1186121N/1186123 N to LS, 11B5520N to FS, 1SF2222N to EV and 11M6922N/11M6924N to SF, travel grants V428023N, K103723N, K217722N to LS. FLvdV was supported by a Vidi grant of the Netherlands Association for Scientific Research. FLvdV, JW, AC and GC were supported by the Europeans Union's Horizon 2020 research and innovation program under grant agreement no 847507 HDM-FUN. AC was also supported by the Fundação para a Ciência e a Tecnologia (FCT), with the references UIDB/50026/2020, UIDP/50026/2020, PTDC/MED-OUT/1112/2021 (https://do
背景:流感相关肺曲霉菌病(IAPA)是流感重症患者的一种严重真菌超级感染,其发病机制尚不完全清楚。尽管使用了抗真菌和抗病毒的现代疗法,但死亡率仍然高得令人无法接受。我们旨在揭示 IAPA 的免疫发病机制,以此开发辅助免疫调节疗法:方法:我们利用小鼠 IAPA 模型来研究流感如何导致侵袭性肺曲霉菌病的发生。免疫功能正常的小鼠在第0天接受流感鼻内注射,4天后经气管接种曲霉菌。每天监测小鼠的总体健康状况、微计算机断层扫描(μCT)肺部病理学检查和生物发光成像(BLI)真菌负荷。终点时,进行高参数免疫分型、空间转录组学、组织病理学、活体成像动态吞噬体生物生成测定、免疫荧光染色、专门的功能性吞噬和杀灭测定:我们发现流感诱导的干扰素-γ(IFN-γ)的早期大量产生是 IAPA 免疫病理的主要驱动因素,并阐明了其分子机制。具体来说,IFN-γ的过度产生导致了Th17免疫应答缺陷、巨噬细胞耗竭以及巨噬细胞对曲霉分生孢子的杀伤力受损,这是由于NADPH氧化酶依赖性激活LC3相关吞噬作用(LAP)受到了抑制。值得注意的是,IFN-γ被部分或完全基因消减的小鼠恢复了Th17免疫反应和依赖LAP的杀灭机制,并完全免于侵袭性真菌感染:总之,这些研究结果表明,病毒诱导的IFN-γ分泌旺盛是IAPA免疫功能障碍的主要驱动因素,为探索将病毒诱导的过量IFN-γ作为IAPA的生物标志物和新的免疫治疗靶点铺平了道路:本研究由佛兰德研究基金会(FWO)资助,JW、SHB和GVV的项目经费为G053121N;GVV的项目经费为G057721N、G0G4820N;KL和GVV的项目经费为1506114 N;鲁汶大学内部基金(C24/17/061)资助 GVV,临床研究基金资助 JW,法兰德斯研究基金会(FWO)1186121N/1186123 N 资助 LS、11B5520N 资助 FS、1SF2222N 资助 EV 和 11M6922N/11M6924N 资助 SF,旅费资助 V428023N、K103723N 和 K217722N 资助 LS。FLvdV得到了荷兰科学研究协会Vidi基金的资助。FLvdV、JW、AC和GC得到了欧盟 "地平线2020 "研究与创新计划(Horizon 2020 Research and Innovation Program)的资助,资助协议编号为847507 HDM-FUN。AC 还得到了巴西科技基金会(FCT)的资助,资助编号为 UIDB/50026/2020、UIDP/50026/2020、PTDC/MED-OUT/1112/2021 (https://doi.org/10.54499/PTDC/MED-OUT/1112/2021) 和 2022.06674.PTDC (http://doi.org/10.54499/2022.06674.PTDC);以及 "la Caixa "基金会的资助,资助编号为 LCF/PR/HR22/52420003 (MICROFUN)。
{"title":"Damping excessive viral-induced IFN-γ rescues the impaired anti-Aspergillus host immune response in influenza-associated pulmonary aspergillosis.","authors":"Laura Seldeslachts, Frederik Staels, Marina Gkountzinopoulou, Cato Jacobs, Birger Tielemans, Eliane Vanhoffelen, Agustin Reséndiz-Sharpe, Lander De Herdt, Jeason Haughton, Teresa Prezzemolo, Oliver Burton, Simon Feys, Frank L van de Veerdonk, Agostinho Carvalho, Lieve Naesens, Patrick Matthys, Katrien Lagrou, Erik Verbeken, Georgios Chamilos, Joost Wauters, Stephanie Humblet-Baron, Greetje Vande Velde","doi":"10.1016/j.ebiom.2024.105347","DOIUrl":"10.1016/j.ebiom.2024.105347","url":null,"abstract":"<p><strong>Background: </strong>Influenza-associated pulmonary aspergillosis (IAPA) is a severe fungal superinfection in critically ill influenza patients that is of incompletely understood pathogenesis. Despite the use of contemporary therapies with antifungal and antivirals, mortality rates remain unacceptably high. We aimed to unravel the IAPA immunopathogenesis as a means to develop adjunctive immunomodulatory therapies.</p><p><strong>Methods: </strong>We used a murine model of IAPA to investigate how influenza predisposes to the development of invasive pulmonary aspergillosis. Immunocompetent mice were challenged with an intranasal instillation of influenza on day 0 followed by an orotracheal inoculation with Aspergillus 4 days later. Mice were monitored daily for overall health status, lung pathology with micro-computed tomography (μCT) and fungal burden with bioluminescence imaging (BLI). At endpoint, high parameter immunophenotyping, spatial transcriptomics, histopathology, dynamic phagosome biogenesis assays with live imaging, immunofluorescence staining, specialized functional phagocytosis and killing assays were performed.</p><p><strong>Findings: </strong>We uncovered an early exuberant influenza-induced interferon-gamma (IFN-γ) production as the major driver of immunopathology in IAPA and delineated the molecular mechanisms. Specifically, excessive IFN-γ production resulted in a defective Th17-immune response, depletion of macrophages, and impaired killing of Aspergillus conidia by macrophages due to the inhibition of NADPH oxidase-dependent activation of LC3-associated phagocytosis (LAP). Markedly, mice with partial or complete genetic ablation of IFN-γ had a restored Th17-immune response, LAP-dependent mechanism of killing and were fully protected from invasive fungal infection.</p><p><strong>Interpretation: </strong>Together, these results identify exuberant viral induced IFN-γ production as a major driver of immune dysfunction in IAPA, paving the way to explore the use of excessive viral-induced IFN-γ as a biomarker and new immunotherapeutic target in IAPA.</p><p><strong>Funding: </strong>This research was funded by the Research Foundation Flanders (FWO), project funding under Grant G053121N to JW, SHB and GVV; G057721N, G0G4820N to GVV; 1506114 N to KL and GVV; KU Leuven internal funds (C24/17/061) to GVV, clinical research funding to JW, Research Foundation Flanders (FWO) aspirant mandate under Grant 1186121N/1186123 N to LS, 11B5520N to FS, 1SF2222N to EV and 11M6922N/11M6924N to SF, travel grants V428023N, K103723N, K217722N to LS. FLvdV was supported by a Vidi grant of the Netherlands Association for Scientific Research. FLvdV, JW, AC and GC were supported by the Europeans Union's Horizon 2020 research and innovation program under grant agreement no 847507 HDM-FUN. AC was also supported by the Fundação para a Ciência e a Tecnologia (FCT), with the references UIDB/50026/2020, UIDP/50026/2020, PTDC/MED-OUT/1112/2021 (https://do","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"108 ","pages":"105347"},"PeriodicalIF":9.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}